Cargando…

Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders

The progressive patterns of neurological disability in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) and the significance of clinical relapses to the progressions of neurological disability in these diseases have not been fully elucidated. In this study, to elucidate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akaishi, Tetsuya, Takahashi, Toshiyuki, Misu, Tatsuro, Abe, Michiaki, Ishii, Tadashi, Fujimori, Juichi, Aoki, Masashi, Fujihara, Kazuo, Nakashima, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431838/ https://www.ncbi.nlm.nih.gov/pubmed/32807848 http://dx.doi.org/10.1038/s41598-020-70919-w

Ejemplares similares

Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Optic neuritis after ocular trauma in anti‐aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence
por: Akaishi, Tetsuya, et al.
Publicado: (2019)

White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease
por: Akaishi, Tetsuya, et al.
Publicado: (2023)

Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
por: Namatame, Chihiro, et al.
Publicado: (2021)

Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Osmotic pressure of serum and cerebrospinal fluid in patients with suspected neurological conditions
por: Akaishi, Tetsuya, et al.
Publicado: (2019)

Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder
por: Asato, Yuko, et al.
Publicado: (2018)

Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks
por: Sato, Douglas Kazutoshi, et al.
Publicado: (2014)

Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody
por: Kurosawa, Kazuhiro, et al.
Publicado: (2015)

Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders
por: Takai, Yoshiki, et al.
Publicado: (2023)

Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica
por: Misu, Tatsuro, et al.
Publicado: (2013)

Cognitive impairment in neuromyelitis optica spectrum disorders: A comparison of the Wechsler Adult Intelligence Scale-III and the Wechsler Memory Scale Revised with the Rao Brief Repeatable Neuropsychological Battery
por: Fujimori, Juichi, et al.
Publicado: (2017)

Epitope Analysis of Cerebrospinal Fluid IgG in Japanese Multiple Sclerosis Patients Using Phage Display Method
por: Fujimori, Juichi, et al.
Publicado: (2011)

White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases
por: Akaishi, Tetsuya, et al.
Publicado: (2022)

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
por: Hillebrand, Sophie, et al.
Publicado: (2018)

Neuromyelitis optica spectrum disorders: still evolving and broadening
por: Fujihara, Kazuo
Publicado: (2019)

Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica
por: Nishiyama, S., et al.
Publicado: (2016)

Sensitivity and specificity of meningeal signs in patients with meningitis
por: Akaishi, Tetsuya, et al.
Publicado: (2019)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
por: Ogawa, Ryo, et al.
Publicado: (2017)

T cell-activation in neuromyelitis optica lesions plays a role in their formation
por: Pohl, Maria, et al.
Publicado: (2013)

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats
por: Kitic, Maja, et al.
Publicado: (2013)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Differential diagnosis of neuromyelitis optica spectrum disorders
por: Kim, Sung-Min, et al.
Publicado: (2017)

Serological markers associated with neuromyelitis optica spectrum disorders in South India
por: Pandit, Lekha, et al.
Publicado: (2016)

Patterns of cortical grey matter thickness reduction in multiple sclerosis
por: Fujimori, Juichi, et al.
Publicado: (2021)

Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?
por: Yamamura, Takashi, et al.
Publicado: (2017)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica
por: Shimizu, Fumitaka, et al.
Publicado: (2015)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Three cases of neuromyelitis optica spectrum disorder
por: Matsusue, Eiji, et al.
Publicado: (2016)

The human central nervous system discharges carbon dioxide and lactic acid into the cerebrospinal fluid
por: Akaishi, Tetsuya, et al.
Publicado: (2019)

Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis
por: Ajitomi, Satori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_atd3dvv12jm1do6n7bojr9l2pm